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A B S T R A C T
Background
Cystic fibrosis is an inherited recessive disorder of chloride transport that is characterised by recurrent and persistent pulmonary infections
from resistant organisms that result in lung function deterioration and early mortality in suFerers.
Meticillin-resistant Staphylococcus aureus (MRSA) has emerged as, not only an important infection in long-term hospitalised patients, but
also as a potentially harmful pathogen in cystic fibrosis, and has been increasing steadily in prevalence internationally. Chronic pulmonary
infection with MRSA is thought to confer cystic fibrosis patients with a worse overall clinical outcome and, in particular, result in an
increased rate of decline in lung function. Clear guidance for the eradication of MRSA in cystic fibrosis, supported by robust evidence from
good quality trials, is urgently needed.
Objectives
To evaluate the eFectiveness of treatment regimens designed to eradicate MRSA and to determine whether the eradication of MRSA confers
better clinical and microbiological outcomes for people with cystic fibrosis.
Search methods
Randomised and quasi-randomised controlled trials were identified by searching the Cochrane Cystic Fibrosis and Genetic Disorders
Group's Cystic Fibrosis Trials Register, PUBMED, MEDLINE, Embase, handsearching article reference lists and through contact with local
and international experts in the field.
Date of the last search of the Group's Cystic Fibrosis Trials Register: 04 September 2014.
Selection criteria
Randomised or quasi-randomised controlled trials comparing any combinations of topical, inhaled, oral or intravenous antimicrobials
with the primary aim of eradicating MRSA compared with placebo, standard treatment or no treatment.
Data collection and analysis
The authors independently assessed all search results for eligibility. No eligible trials were identified for inclusion.
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Main results
No current published eligible trials were identified, although three ongoing clinical trials are likely to be eligible for inclusion in future
updates of this review.
Authors' conclusions
We did not identify any randomised trials which would allow us to make any evidence-based recommendations. Although the results
of several non-randomised studies would suggest that, once isolated, the eradication of MRSA is possible; whether this has a significant
impact on clinical outcome is still unclear. Further research is required to guide clinical decision making in the management of MRSA
infection in cystic fibrosis.
P L A I N   L A N G U A G E   S U M M A R Y
Interventions to clear meticillin-resistant Staphylococcus aureus (MRSA) from the lungs of people with cystic fibrosis
Review question
We looked for evidence to determine the eFect of diFerent ways of clearing meticillin-resistant Staphylococcus aureus (MRSA) from the
lungs of people with cystic fibrosis.
Background
Meticillin-resistant Staphylococcus aureus (MRSA), is the name given to a particular bacteria which is resistant to some types of antibiotics.
This is particularly worrying for people with cystic fibrosis, which is an inherited condition that causes thick mucus to build up in the lungs.
It is very diFicult for people with cystic fibrosis to cough up this thick mucus, making it an ideal breeding ground for bacteria, including
MRSA, and making these people more prone to chest infections. It is thought that MRSA can cause more damage than other bacteria which
are not resistant to antibiotics. We wanted to identify research evidence to support the best way for treating MRSA infections and also to
see if this would improve the lives of people with cystic fibrosis.
Search date
The evidence is current to: 04 September 2014.
Key results
Unfortunately, we could not find any trials which compared treating MRSA to not treating MRSA, or which compared one form of treatment
to another. We are unable, therefore, to make any recommendations for its management at this point in time.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is the most common autosomal inherited
condition in the Caucasian population, with a gene carrier rate
of 1 in 25 and aFecting around 1 in 2500 newborns in the UK
(CF Trust UK 2011). It is a multisystem disorder resulting from
a disruption in chloride transport at the cellular level leading to
abnormal, dehydrated secretions within the lungs. This results in
impaired mucociliary clearance leading to recurrent pulmonary
infections, bronchiectasis and progressively deteriorating lung
function, which is the main cause of the morbidity and mortality
seen in CF.
Organism
The abbreviation MRSA stands for meticillin-resistant
Staphylococcus aureus (S. aureus). Meticillin is an antibiotic that is
no longer in clinical use, but MRSA is resistant to antibiotics within
the same class. This includes flucloxacillin, which is prescribed
both for prophylaxis and treatment of infection with S. aureus in
people with CF in the UK. Furthermore, MRSA is also resistant to
other antibiotics in the beta lactam family such as cephalosporins
(e.g. ceIazidime) and carbapenems (e.g. meropenem). Resistance
is not due to production of beta lactamase enzymes, but rather to
the production of altered penicillin-binding proteins coded on the
mecA gene.
Most MRSA infections in both the non-CF and CF populations have
been so-called 'healthcare associated' (HA-MRSA), which occur in
patients who have been hospitalised, had surgery, are on dialysis,
or who have had invasive procedures. However, in recent years
outbreaks of 'community-acquired' MRSA (CA-MRSA) have occurred
in otherwise healthy people with no link to a healthcare facility
(Chambers 2009). This distinction by patient location at time of
infection is becoming increasingly diFicult, given outbreaks of
strains of CA-MRSA in hospitals, and the spread of HA-MRSA strains
in the community through people with chronic illnesses.
It is possible to further classify MRSA according to the
staphylococcal chromosome cassette mec (SCCmec) type, on which
the mecA gene is located. Several distinct types have been
described to date, of which HA-MRSA is associated with types I to
III. These SCCmec types also encode for resistance to other classes
of antibiotics, thus making HA-MRSA overall more resistant. So-
called CA-MRSA carries SCCmec types IV and V. Although CA-MRSA
usually has the smaller type IV SCCmec type, which lacks some
of the antibiotic resistance determinants possessed by types I to
III, it is also more frequently associated with the production of
the virulence factor Panton-Valentine leucocidin (PVL), a cytotoxin
which causes leucocyte destruction and tissue necrosis.
Although patients with MRSA have been found to require a
higher intensity of treatment when compared with their meticillin-
sensitive S. aureus (MSSA) counterparts, this is further complicated
by diFerences observed between diFerent MRSA types (Muhlebach
2011). For instance, the emergence of PVL-positive CA-MRSA within
the CF population has been described and one report suggests
this to be associated with a more severe clinical course acutely
compared with PVL-negative CA- or HA-MRSA strains (Elizur 2007).
Prevalence
The prevalence of MRSA varies throughout Europe. As reported by
the European Centre for Disease Prevention and Control, in the UK
25% to 50% of isolates of S. aureus are found to be MRSA compared
to less than 1% in Norway (ECDC 2009). In the USA, the proportion of
healthcare-associated S. aureus infections found in intensive care
units that are attributable to MRSA has increased from 2% in 1974
to 64% in 2004 (Klevens 2006).
Amongst people with CF, the prevalence of chronic MSSA (defined
as three or more recorded isolates) in the UK has increased from
7.3% in 2001 to 15.2% in 2009, with the prevalence of MRSA (defined
as any single isolate) at 2.5% (CF Trust 2009).
The USA CF registry data from 2009 recorded any isolate of MSSA
at 51.3% and any isolate of MRSA at 23.7%, with 65.8% of their
CF population having positive cultures for either MSSA or MRSA
(CF Foundation 2009). The most recent 2010 data reports the
prevalence of MSSA at 67% and MRSA at 25.7% (CF Foundation
2010).
In Australia, the 2009 CF registry reports a MSSA prevalence of 43%
and MRSA prevalence of 4.2% as a proportion of tested patients via
any culture method and including any single positive isolate (Cystic
Fibrosis Australia 2011).
Condition
As described above, one of the early key pathogens in CF-lung
disease is MSSA, but increasingly MRSA has been cultured from the
lower respiratory tracts of people with CF. The role of MRSA in CF-
lung disease remains debated.
A large observational study looking at 1834 patients who had
positive respiratory cultures for S. aureus (MRSA or MSSA) found
that presence of MRSA in respiratory cultures was associated
with poorer lung function, more courses of antibiotics and longer
hospital stays when compared with those colonised with MSSA (Ren
2007). However, the authors were unable to conclude whether their
findings were due to cause or eFect.
Two studies were published in 2008 addressing this point, but
came to diFering conclusions (Dasenbrook 2008; Sawicki 2008).
Dasenbrook suggested that chronic, though not intermittent,
detection of MRSA in respiratory tract cultures of people with CF (as
defined by reports from the CF Foundation Registry) is associated
with poorer survival and reduced lung function (Dasenbrook 2008;
Dasenbrook 2010). By contrast, Sawicki concluded that although
MRSA was a marker for more aggressive therapy and may reflect
increased disease severity, MRSA detection was not associated with
a significant decline in lung function (Sawicki 2008).
Although both were longitudinal studies, Sawicki analysed data
from an observational study of people with CF in North America
(Epidemiologic Study of Cystic Fibrosis (ESCF) (Morgan 1999))
using multivariate linear regression analysis to study the impact
of MRSA on lung function (forced expiratory volume in one second
(FEV1) per cent (%) predicted); whilst Dasenbrook used data from
the CF Foundation Registry. One of the fundamental diFerences
between the two studies is the inclusion criteria. Sawicki included
patients for analysis who had only one positive culture for MRSA
(23% of cohort) whilst Dasenbrook studied patients with three or
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (Review)









Cochrane Database of Systematic Reviews
more positive cultures, those with one or two MRSA cultures were
excluded.
Despite these diFerences, both studies reported an increased rate
of decline in FEV1 % predicted of around 0.5% in their 'before'
and 'aIer' MRSA groups. It is possible that this did not reach
statistical significance in the Sawicki paper secondary to the
smaller cohort size (593 versus 1732). An increased rate of decline
of 0.8% has more recently been reported by a group in Belgium
who conducted a retrospective case-control study based at a single
centre (Vanderhelst 2012).
In terms of survival, Dasenbrook found that detection of MRSA from
the respiratory tract of CF patients was associated with a risk of
death 1.27 (95% confidence interval (CI) 1.11 to 1.45) times that of
individuals in whom MRSA had never been detected (Dasenbrook
2010). Perhaps of more clinical importance however, is that they
also found that patients who clear MRSA within one year have the
same risk of death as those who never have a positive culture for
MRSA. This emphasizes the importance and need for clear guidance
on how we manage MRSA infection in CF.
Description of the intervention
Currently in the UK, children are prescribed prophylactic anti-
staphylococcal antibiotics (flucloxacillin) from diagnosis until three
years of age with resultant fewer isolates of S. aureus, though the
clinical significance of this finding remains uncertain (Smyth 2003).
   However, the US Cystic Fibrosis Foundation recommend against
the use of prophylaxis in anticipation that this may lead to an
increase in colonisation of Pseudomonas aeruginosa (P. aeruginosa)
(Flume 2007).
Some authors suggest a pragmatic approach would be to treat
every isolate of MRSA or MSSA with eradication therapy (Solis
2003). However, this approach, with its frequent use of antibiotics,
would run the risk of increasing the incidence of multi-resistant
organisms that are less susceptible to treatment, whilst potentially
adding to the already substantial treatment burden that people
with CF face.
Certainly in the case of HA-MRSA infections, there has been
encouraging progress since the introduction of stringent MRSA
screening and eradication measures in hospitals. The 2010 report
by the Centers for Disease Control and Prevention showed a
28% decline in invasive MRSA infections originating in hospitals
between 2005 and 2008 in the USA (Kallen 2010). Whilst in the
UK, the Department of Health target to reduce MRSA bloodstream
infections by 50% from its peak levels in 2003 to 2004 was achieved
by 2008 (Liebowitz 2009; Pearson 2009).
Why it is important to do this review
Despite the increasing prevalence of MRSA, its clinical significance
remains unclear and there remains no international consensus
for its management. With the increasing prevalence of resistant
strains of S. aureus, it becomes more important for any therapeutic
approaches with antibiotics to be justified with the most up-to-date
evidence, especially in patients with chronic medical conditions.
A previous Cochrane review could not find enough evidence to
support the use of any single or combination of therapies for
eradicating nasal or extra-nasal colonisation of MRSA over another
(Loeb 2003). Most studies addressing MRSA colonisation have
been done in either healthy carriers or people in chronic care
facilities, but not in those with chronic lung disease as seen in
CF. Such reports include a variety of interventions, oIen focusing
on nasal and skin colonisation, thus such findings may not be
directly applicable to CF. However, a retrospective review of
MRSA eradication practice in a single large UK adult CF centre
showed some promise (Doe 2010). They used varying eradication
regimes based on sensitivity patterns and individual tolerability,
including stringent patient segregation and topical decolonisation,
to attempt MRSA eradication from sputum and skin in CF patients.
Over a 10-year period they reported an eradication rate of 81%
(defined as three consecutive negative sputum and peripheral
cultures over six months), though the clinical impact of what
successful MRSA eradication meant for patients was not reported.
The 2008 UK CF Trust consensus statement document stated that in
the absence of prospective randomised clinical trials looking at the
eFect on lung function which chronic carriage with MRSA confers,
MRSA infection will lead to a reduction in antibiotic treatment
options and a likelihood of a deterioration in lung function. It
is therefore their recommendation that the eradication of MRSA
should be attempted for positive cases (CF Trust 2008).
The rationale for this review is to determine the success of MRSA
eradication for people with CF, and to question whether eradication
confers improved clinical outcomes. This version of the review is an
update of the original review (Lo 2013).
O B J E C T I V E S
To evaluate the eFectiveness of treatment regimens designed to
eradicate MRSA and to determine whether the eradication of MRSA
confers better clinical and microbiological outcomes for patients
with CF.
To ascertain whether attempts at eradicating MRSA can lead to
increased acquisition of other resistant organisms (including P.
aeruginosa) or increased adverse eFects from drugs, or both.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised or quasi-randomised controlled trials.
Types of participants
Children and adults diagnosed with CF clinically and by sweat
or genetic testing with a confirmed positive microbiological
isolate of MRSA on clinically relevant CF respiratory cultures
(bronchoalveolar lavage (BAL), cough or oropharyngeal swab,
spontaneous or induced sputum culture) specimen prior to
enrolment into the trial.
We included all disease severities. We did not include patients with
nasal carriage of MRSA alone in this review.
Types of interventions
Any combinations of topical, inhaled, oral or intravenous
antimicrobials with the primary aim of eradicating MRSA once
detected on clinically relevant CF respiratory cultures compared
with placebo, standard treatment or no treatment.
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Types of outcome measures
Primary outcomes
1. Eradication of MRSA (as defined by negative respiratory culture
aIer completion of the eradication protocol)




a. forced expiratory volume at one second (FEV1) % predicted
b. forced vital capacity (FVC) % predicted
c. other validated measures of lung function
2. Overall antibiotic use
3. Mortality
4. Quality of life measured using a validated tool
a. CF Questionnaire-Revised version (CFQ-R) (Quittner 2009)
b. CF Quality of Life Questionnaire (CFQoL) (Gee 2000)
5. Isolation of MRSA or other organisms with new antibiotic
resistant phenotypes
a. P. aeruginosa
b. other previously uncultured organism
c. small colony variants
6. Growth and nutritional status
a. weight (kg)
b. height (cm)
c. body mass index (BMI) (kg/m2)
d. lean body mass (%)
e. fat body mass (%)
7. Adverse eFects to treatment
a. mild (not requiring treatment)
b. moderate (requiring treatment or admission or cessation of
treatment, or a combination of any of these)
c. severe (life-threatening)
8. Elimination of carrier status (nasal or skin)
9. Frequency of exacerbations
10.Cost of care
Search methods for identification of studies
Electronic searches
We identified relevant studies from the Group's Cystic Fibrosis
Trials Register using the terms: (Staphylococcus aureus OR mixed
infections) AND (eradication OR unknown).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
weekly searches of MEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis
conferences: the International Cystic Fibrosis Conference; the
European Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group Module. Date of the latest
search of the Group's CF Register: 04 September 2014.
We searched for relevant trials via the websites
www.clinicaltrials.gov and www.isrctn.org using the search terms
(Cystic Fibrosis AND MRSA). Date of latest search: 10 December
2014.
We also independently searched PUBMED, MEDLINE (1950 to
December 2014) and Embase (1980 to December 2014) via the
OpenAthens access management system using the search strategy
detailed below - see Appendix 1. Date of latest search: 10 December
2014.
Searching other resources
We will also contact primary authors and research institutions of
any future identified trials for unpublished data.
Data collection and analysis
We were unable to identify any eligible and completed trials
for inclusion in this review. We have detailed our methodology
for selection of trials and also the planned methodology for
data analysis should eligible studies become available in future
searches.
Selection of studies
Two authors (DL, MH) independently screened trials for inclusion in
this review using methods in accordance with methods described
by Higgins in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). Both authors independently
examined the title and abstracts to exclude duplicate publications,
case reports, review articles and unrelated articles. Of the
remaining studies, DL and MH independently examined the full text
publications to determine if they met our eligibility criteria. The
authors planned to resolve any disagreements on the eligibility of
studies by consulting with the third and fourth authors (MM, AS) for
advice and reaching a consensus through discussion between all
authors.
Data extraction and management
Should any eligible studies become available in future searches,
two authors (DL, MH) will extract data using standardised data
acquisition forms upon which all authors have agreed. They
will resolve disagreements through discussion between all four
authors. Where information is incomplete or unclear, the authors
will attempt to contact the lead author of the paper where possible.
The authors plan to group outcome data into those measured at up
to 14 days, up to 1 month, up to 3 months, up to 6 months and up
to 12 months aIer MRSA therapy. All authors will consider data for
inclusion which was recorded at other time intervals and highlight
this in the report.
Assessment of risk of bias in included studies
The authors will assess the risk of bias using methods described
in theCochrane Handbook for Systematic Reviews for Interventions
(Higgins 2011b). In particular each author will examine the methods
to determine the adequacy of randomisation and blinding, and also
whether any participants lost to follow-up are accounted for and
justified. They will also seek to identify any selective reporting by
comparing the full report to the protocol.
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In addition, each author will independently use the 'risk of bias'
assessment tool available in section 8.5 of the Cochrane Handbook
for Systematic Reviews for Interventions in order to judge each of the
described seven domains as having low, high or unclear risk of bias
(Higgins 2011b).
Measures of treatment e=ect
For dichotomous data (e.g. eradication achieved or not), the
authors plan to analyse the data on an intention-to-treat basis,
irrespective of compliance or dropout secondary to adverse eFects.
They will sort the data based on each possible outcome event for
each treatment arm and calculate the odds ratio (OR) and its 95%
CI.
For continuous data, the authors plan to calculate the mean
diFerence (MD) of eFect of each variable along with its 95% CI.
Where two or more studies measure the same outcome but using
diFerent scales, they aim to calculate the standardised mean
diFerence (SMD) with its 95% CI.
The authors plan to extract ordinal and count data in all forms
in which they are reported and plan to analyse these as per
continuous data for common outcomes; for rare outcomes they
will follow the advice in section 9.2.5 of theCochrane Handbook for
Systematic Reviews of Interventions (Deeks 2011).
For time-to-event data (e.g. time to next exacerbation), they plan to
calculate the hazard ratio (HR) at individual time points (at 14 days,
then 1, 3, 6 and 12 months) along with its 95% CI.
Unit of analysis issues
Cross-over studies are not eligible for inclusion within this review
since the authors are reviewing how eFicacious the initial attempt
at eradication of MRSA is when compared with placebo, usual
treatment or no treatment. Subsequently, they aim to evaluate
time until next positive MRSA culture and number of further courses
of antibiotics required following each arm of therapy.
The authors do not plan to include cluster-randomised controlled
trials. When randomisation is performed according to patient
groups, certain strains of MRSA (which may diFer between
communities) could potentially be over-represented in either the
treatment or placebo arm and hence bias the results.
Dealing with missing data
In cases where data are missing which relate to either the review's
primary or secondary outcomes, the authors will attempt to contact
the primary investigator for clarification. If they are not able to
contact the primary investigator, they will attempt to contact the
co-investigators and sponsors.
Assessment of heterogeneity
In order to assess heterogeneity between studies the authors
will use the I2 statistic and the chi-squared test. As stated in
theCochrane Handbook for Systematic Reviews of Interventions,
the importance of the observed value of I2 depends on (i) the
magnitude and direction of eFects and (ii) the strength of evidence
for heterogeneity (e.g. P value for chi-squared) (Higgins 2011a). The
authors will consider values of 0% to 40% to represent little to
no heterogeneity, 30% to 60% moderate, 60% to 90% substantial
and values of more than 90% as demonstrating considerable
heterogeneity.
Assessment of reporting biases
The authors plan to assess for selective reporting of results by
comparing (where available) the outcomes listed in the original
protocol to those reported in the final paper. They will also search
clinical trials registers for any completed studies relevant to our
review that may not have been published. They plan to attempt to
contact the primary investigators of identified trials to determine
whether they are aware of any relevant unpublished data. This
may help to identify some small studies which may not have
reported statistically significant outcomes. The authors aim to
identify publication bias with the construction of funnel plots,
although they are wary of other potential causes for asymmetry.
Data synthesis
The authors aim to analyse extracted data using a fixed-eFect meta-
analysis unless the heterogeneity between studies is found to be
substantial (more than 60%), at which point they will perform a
random-eFects meta-analysis.
Subgroup analysis and investigation of heterogeneity
If the authors identify a suFicient number of studies (more than 10)
and also find substantial heterogeneity between studies, they will
investigate this with subgroup analysis of the following:
1. eradication therapy commenced at initial acquisition versus
following chronic colonisation (three or more positive cultures
over a 12-month period);
2. duration of eradication therapy (up to and including 6 weeks, 7
to 12 weeks, over 12 weeks);
3. intravenous versus aerosolised versus oral administration of
antibiotics;
4. eFicacy of regimens which include methods for skin or nasal
eradication, or both, versus those that do not.
Sensitivity analysis
Where outcome measures have been chosen based upon arbitrary
values, the authors plan to re-evaluate the eFect that alternative
endpoints have on their findings. For instance, some studies may
use a cut-oF of longer than 14 days to represent successful
eradication of MRSA, where the available data allows, the authors
will repeat the analysis of treatment eFect using diFerent cut-oFs
(1, 3, 6 or 12 months).
With regards to smaller studies (20 participants in each group or
less) that the authors may include in the initial meta-analyses,
they aim to repeat the analyses without these smaller studies to
determine their eFect.
R E S U L T S
Description of studies
Results of the search
A total of 54 references to 41 studies were identified from
the CFGD Group's CF Trials Register. Seven additional studies
were identified from a separate PUBMED, EMBASE and MEDLINE
search. Three ongoing studies were identified from the ongoing
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trials registers www.clinicaltrials.gov and www.isrctn.org. These
ongoing trials may be eligible for inclusion into future
versions of this review: 'Early meticillin-resistant Staphylococcus
aureus (MRSA) therapy in cystic fibrosis (CF)' (NCT01349192),
'Persistent meticillin-resistant Staphylococcus aureus eradication
protocol' (NCT01594827) and 'EFicacy and safety study of AeroVanc
for the treatment of persistent MRSA lung infection in cystic fibrosis
patients' (NCT01746095). Details of these studies can be found in
the tables (Characteristics of ongoing studies). Please also see the
PRISMA diagram (Figure 1).
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Figure 1.   Study flow diagram.
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Included studies
The authors did not identify any studies which were eligible for
inclusion in the current version of this review.
Excluded studies
Of the 41 excluded studies from the results of the search of the
Cystic Fibrosis and Genetic Disorders Group's CF Trials Register,
12 were pharmacokinetic studies, one was a tolerability study
and the remaining 28 were excluded because the participants or
interventions were not relevant to our review (See: Characteristics
of excluded studies). None of the 41 studies had the primary intent
of MRSA eradication in people with CF.
Of the seven additional studies identified, all had relevant
participants, interventions and outcomes but these were not
included as they were not randomised or controlled studies. All
had the primary aim of MRSA or S.aureus (one study) eradication
in people with CF. Two were case reports, one of a 10-year old
boy (Maiz 1998) and one of a 28-year old man (Serisier 2004). Four
were observational studies (Garske 2004; Macfarlane 2007; Dalbøge
2013; Vanderhelst 2013) and one was a retrospective study (Solis
2003).
Risk of bias in included studies
No studies were identified which were eligible for inclusion in this
review.
E=ects of interventions
No studies were identified which were eligible for inclusion in this
review.
D I S C U S S I O N
Summary of main results
Although MRSA is an important emerging pathogen in CF
respiratory illness, there is no widely accepted consensus for
its optimal management. The broad search terms used in this
review identified a large number of studies listed on the Cochrane
CFGD Group's CF Trials Register, unfortunately none of them were
relevant or eligible for inclusion. Most of the studies identified dealt
primarily with P. aeruginosa treatment in CF and not with MRSA.
Overall completeness and applicability of evidence
There are currently three ongoing prospective studies awaiting
completion, which will potentially be eligible for inclusion in future
versions of this review. One study examines the eradication of early
MRSA acquisition, whilst the other two examines management
of persistent infection (see Characteristics of ongoing studies).
One of these is currently recruiting participants and is estimated
to complete in March 2015 (NCT01594827) whilst the other two
studies have completed patient enrolment and results are awaited
(NCT01349192 and NCT01746095). All three studies will compare an
active treatment group to an observational/placebo group.
Quality of the evidence
The available evidence for this review is poor, with no published
randomised controlled trials and only a few observational or
retrospective studies at present.
Potential biases in the review process
One of the co-authors of this review (MM) is the lead investigator of
one of the ongoing clinical trials (NCT01349192).
Agreements and disagreements with other studies or
reviews
Various strategies have been proposed for the eradication of MRSA
when isolated from CF respiratory samples. It has become apparent
from this review that these are based on anecdotal evidence or,
at best, a small number of observational studies involving small
numbers of participants.
The authors identified seven non-randomised and non-controlled
studies; three in paediatric participants (age range 1 to 16 years),
two in adults (age range 22 to 36 years) and two in mixed paediatric
and adult groups. With the exception of Maiz 1998 (a case report
on one 10-year old boy), and Dalbøge 2013 (a cohort study which
reports on eFicacy of S.aureus eradication, where only 0.3% of
subjects were MRSA positive), the remaining five studies reported
successful eradication of MRSA in, at least a proportion of, their
participants (Garske 2004; Macfarlane 2007; Serisier 2004; Solis
2003; Vanderhelst 2013).
Whilst in the Maiz 1998 case report MRSA was not eradicated
aIer the 17-month treatment with daily continuous inhaled
vancomycin, the authors did report improvements in lung function
and symptom score in the child. The Vanderhelst 2013 study
reported a non-statistically significant trend in improvement of
FEV1% in the 11 patients they studied, aIer successful eradication
of MRSA. The largest cohort study (Dalbøge 2013) successfully
eradicated Staphylococcus aureus from the sputum samples of the
65 patients they treated, and reported a statistically significant
median (range) improvement in FEV1% predicted of 3.3% (−25%
to 36%, p<0.0001). However, they did not diFerentiate between
those patients who grew MSSA or those who grew MRSA from their
sputum.
This is contradictory to two other studies, which reported no
significant diFerences in lung function between participants who
were successfully eradicated when compared to those who were
not (Garske 2004; Solis 2003); however, this may be because the
numbers were too small to detect a diFerence. The final two studies
reported successful eradication of MRSA, Macfarlane 2007 (in 94%
of patients) and Serisier 2004 (in one 28-year old), but did not
report on lung function or patient clinical status during or following
eradication.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is currently no published evidence from randomised
controlled trials to support any one eradication regimen over
another. While there are reports of successful eradication in those
with CF, there is considerable uncertainty whether this is associated
with patient benefit.
Implications for research
This review has highlighted the lack of evidence behind the present
management of MRSA respiratory infections in CF and emphasizes
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the need for well-designed, adequately-powered trials with long-
term follow-up in order to address this.
These will need to address the questions.
1. Does eradication of MRSA confer a favourable prognosis (see
Types of outcome measures) for people with CF?
2. What is the optimal duration of treatment?
3. What is the most eFective method of providing treatment (oral
or intravenous or inhaled)?
4. Are there any pitfalls to treating MRSA aggressively (i.e. selection
for other resistant pathogens, reduced patient tolerability)?
The published reports of the two ongoing studies identified are
keenly awaited and the authors look forward to assessing the
published data of these for inclusion into a future update of this
review.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adeboyeku 2001 Not a relevant intervention - tolerability study of differing dosages of nebulised colistin.
Amelina 2000 Not a relevant intervention or participants - difference in quality of life between home versus hos-
pital IV treatment.
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Study Reason for exclusion
Carswell 1987 Not relevant participants - trial of P. aeruginosa treatment.
Chua 1990 Not a relevant intervention - used differing tonicities of inhaled antibiotics to assess airway respon-
siveness.
Conway 1996 Not relevant participants - did not differentiate between organisms causing exacerbation leading
to inclusion into the trial.
Cooper 1985 Not relevant participants - trial of P. aeruginosa treatment.
Dalbøge 2013 An observational study. Not randomised.
Davis 1987 Pharmocokinetic study.
Degg 1996 Not a relevant intervention or relevant participants - study on long-term effects of gentamicin on
hearing. Participants not selected on basis of microbial colonisation.
Dodd 1997 Not a relevant intervention or relevant participants - testing differences in lung function relating to
tonicity of nebulised colistin.
Dodd 1998 Not a relevant intervention or relevant participants - a compliance study. No suitable control.
Garske 2004 An observational study.
Geller 2004 Pharmocokinetic study.
Goldfarb 1986 Pharmocokinetic study.
Griffith 2008 Pharmocokinetic/tolerability study.
Gulliver 2003 Not a relevant intervention or relevant participants - testing whether nebulised IV tobramycin solu-
tion induced cough or bronchoconstriction or both.
Heininger 1993 Not relevant participants - trial of P. aeruginosa treatment.
Hjelte 1988 Not relevant participants - investigated affect of home IV antibiotics for P. aeruginosa on quality of
life.
Huang 1979 Not relevant participants - did not differentiate between organisms causing exacerbation leading
to inclusion into trial.
Huls 2000 Pharmocokinetic study.
Junge 2001 Not relevant participants - investigating risk of ototoxicity or cochlea damage in once daily versus
3-times daily IV tobramycin.
Kapranov 1995 Not relevant participants - trial of P. aeruginosa treatment.
Keel 2011 Pharmocokinetic study.
Keller 2010 Pharmocokinetic study.
Knight 1979 Not relevant participants - trial of P. aeruginosa treatment.
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Study Reason for exclusion
Labiris 2004 Not a relevant intervention or relevant participants - objective was to determine whether preserva-
tive containing inhaled tobramycin causes airway inflammation.
Loening -Bauke 1979 Not a relevant intervention - used cephalexin as prophylaxis.
Macfarlane 2007 An observational study.
Maiz 1998 A case report of one 10-year old boy.
Nathanson 1985 Not relevant participants - trial of P. aeruginosa treatment.
Nolan 1982 Not a relevant intervention - prophylaxis rather than eradication.
Pai 2006 Pharmocokinetic study.
Postnikov 2000 Not relevant participants - compared children with CF and aplastic anaemia
Postnikov 2001a Not a relevant intervention or relevant participants - describes risk of quinolone arthropathy in
children.
Postnikov 2001b Not a relevant intervention or relevant participants - investigated the effect on growth with the ad-
dition of ciprofloxacin to the treatment of children with CF.
Ramstrom 2000 Not a relevant intervention - compared quality of life scores in patients who received pre-made in-
fusion devices compared to those who reconstituted drugs themselves.
Roberts 1993 Pharmocokinetic study.
Romano 1991 Not relevant participants - trial of P. aeruginosa treatment.
Rosenfeld 2006 Pharmocokinetic study.
Sahl 1992 Not relevant participants - MRSA not required for entry into study.
Serisier 2004 A case report of one 28-year old man.
Shapera 1981 Not relevant participants - did not differentiate between MRSA and MSSA in inclusion criteria. Un-
clear how randomisation was achieved.
Smith 1997 Pharmocokinetic study.
Solis 2003 Retrospective study.
Stutman 1987 Not relevant participants - pharmacokinetic study of P. aeruginosa treatment.
Vanderhelst 2013 An observational study. Not randomised.
Vitti 1975 Pharmocokinetic study.




MRSA: meticillin-resistant Staphylococcus aureus
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MSSA: meticillin-sensitive Staphylococcus aureus
P. aeruginosa: Pseudomonas aeruginosa
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Early meticillin-resistant Staphylococcus aureus (MRSA) therapy in cystic fibrosis (CF) (STAR-Too).
Methods Randomized, open-label, multicentre study comparing use of an eradication protocol to an obser-
vational group receiving the current standard of care, i.e. treatment for MRSA only with pulmonary
exacerbations.
Participants Participants will include people ≥4 and ≤45 years with CF and new isolation of MRSA from their res-
piratory culture on a routine clinic visit. Estimated enrolment is 80.
Interventions Eradication protocol: 14-day oral rifampicin plus TMP-SMX or minocycline in people with con-
traindications to TMP-SMX.
Observational group: current standard of care, i.e. treatment for MRSA only with pulmonary exac-
erbations.
Drug: rifampin (adult dose: 300 mg twice daily for 14 days; paediatric dose: <40 kg: 15 mg/kg daily
for 14 days divided every 12 hours).
Drug: TMP-SMX (adult dose: 320/1600 orally twice daily for 14 days; paediatric dose: <40 kg: 8 mg/
kg trimethoprim, >40 mg/kg sulfamethoxazole twice daily for 14 days).
Drug: minocycline (only participants 8 years of age or older, who are not able to tolerate TMP/SMX
or whose screening MRSA is resistant to TMP/SMX, should be prescribed minocycline. Adult dose:
100 mg orally twice daily for 14 days. Paediatric dose: <50 kg: 2 mg/kg orally twice daily for 14 days
not to exceed 200 mg per day).
Drug: mupirocin (1 g 2% nasal ointment generously applied to each nostril using a cotton swab
twice daily for 14 days).
Drug: chlorhexidine gluconate oral rinse (0.12% chlorhexidine gluconate oral rinse twice daily for
14 days).
Drug: 2% chlorhexidine solution wipes (whole body wash solution wipes once daily for the first 5
days).
Behavioral: environmental decontamination (wipe down high-touch surfaces and medical equip-
ment with surface disinfecting wipes daily for the first 21 days. Wash all linens and towels in hot
water once weekly for 3 weeks).
Outcomes Primary outcome measure
1. Proportion of participants in each arm with MRSA-negative respiratory cultures at day 28.
 
Secondary outcome measures
1. Proportion of participants treated with oral, inhaled, and IV antibiotics over the 6-month study
and number of days of use.
2. Proportion of participants with a protocol-defined pulmonary exacerbation between baseline
and day 28 who are treated with antibiotics active against MRSA.
Starting date April 2011.
Contact information Marianne S Muhlebach, MD, University of North Carolina, Chapel Hill.
Notes Study closed for enrolment but some participants are still being actively followed up. Data analyses
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Trial name or title Persistent meticillin resistant Staphylococcus aureus eradication protocol (PMEP).
Methods Randomised, placebo-controlled parallel trial.
Duration 28 days with additional 3-month follow-up.
Participants will be assigned in a 1:1 ratio to either treatment or control group.
Participants 40 participants with persistent respiratory tract MRSA infection will be enrolled in this trial.
Inclusion criteria:
1. male or female ≥ 12 years of age;
2. confirmed diagnosis of CF based on the following criteria: positive sweat chloride > 60 mEq/liter
(by pilocarpine iontophoresis) and/or a genotype with 2 identifiable mutations consistent with CF
or abnormal NPD, and 1 or more clinical features consistent with the CF phenotype;
3. written informed consent (and assent when applicable) obtained from participant or partici-
pants's legal representative and ability for participant to comply with the requirements of the
study;
4. 2 positive MRSA respiratory cultures in the last 2 years at least 6 months apart, plus a positive
MRSA respiratory culture at screening visit and run-in (day 14) visit;
5. at least 50% of respiratory cultures from the time of the first MRSA culture (in the last 2 years) have
been positive for MRSA;
6. FEV1 > 30% of predicted normal for age, gender, and height at screening;
7. females of childbearing potential must agree to practice 1 highly effective method of birth con-
trol, including abstinence. Note: highly effective methods of birth control are those, alone or in
combination, that result in a failure rate less than 1% per year when used consistently and cor-
rectly. Female participants who utilize hormonal contraceptives as a birth control method must
have used the same method for at least 3 months before study dosing. If the participant is using
a hormonal form of contraception, she will be required to also use barrier contraceptives as ri-
fampin can affect the reliability of hormone therapy. Barrier contraceptives such as male condom
or diaphragm are acceptable if used in combination with spermicides.
Interventions Treatment group: 28-day course of inhaled vancomycin for inhalation (250 mg twice-a-day) plus
oral rifampicin and oral TMP/SMX.
Control group: taste-matched inhaled placebo (sterile water) plus oral rifampicin and oral TMP/
SMX.
In addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or doxycy-
cline, protocol determined), mupirocin intranasal cream and chlorhexidine body washes.
Outcomes Primary objectives
1. To determine the efficacy of an aggressive treatment protocol in eradicating persistent MRSA in-
fection in individuals with CF.
2. To determine the safety of an aggressive treatment protocol in eradicating persistent MRSA in-
fection in individuals with CF.
Secondary objectives
1. To determine the efficacy of an aggressive treatment protocol in improving FEV1, time to next ex-
acerbation, and quality of life in individuals with CF and persistent MRSA infection.
2. To determine if there is benefit to adding nebulized vancomycin to an aggressive oral antibiotic
treatment protocol in eradicating persistent MRSA infection in individuals with CF.
Starting date Oct 2012.
NCT01594827 
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Contact information Michael Boyle, Associate Professor of Medicine, Johns Hopkins University.




Trial name or title Efficacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic
fibrosis patients.
Methods Randomised, double-blind, placebo-controlled trial.
Duration 28 days with additional 56 days follow up.
There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to
placebo) participants. In Cohort 1, participants will be randomized to receive the 32 mg dose of
AeroVanc twice daily or placebo twice daily. Prior to starting enrolment in Cohort 2, a safety eval-
uation will be carried out by the DMC based on treatment data from the first 20 participants in Co-
hort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safe-
ty, the dose for the active arm in Cohort 2 will be escalated to 64 mg twice daily. Optionally, the ac-
tive arm for Cohort 2 may also be kept the same (32 mg twice daily), or reduced to 16 mg twice dai-
ly, depending on the outcome of the DMC's safety evaluation.
Participants 87 participants with persistent respiratory tract MRSA infection have been enrolled onto this trial.
Inclusion criteria:
1. adults ≥18 years old (and the legally authorized representatives of children ≥12 but <18 years old).
Children ≥12 but <18 years old: able to communicate with site personnel and to understand and
voluntarily sign the assent form;
2. able and willing to comply with the protocol, including availability for all scheduled study visits;
3. have a confirmed diagnosis of CF, determined by having clinical features consistent with the CF
phenotype, plus 1 of the following: a) positive sweat chloride test (value ≥60 mEq/L), or b) geno-
type with two mutations consistent with CF (i.e., a mutation in each of the CFTR genes);
4. be ≥12 years old at time of informed consent form or assent form signing;
5. have sputum culture positive for MRSA at screening, with at least 10,000 CFUs/mL of MRSA;
6. in addition to the screening sample, have at least 2 historical respiratory tract cultures (i.e., spu-
tum and/or throat swab) positive for MRSA prior to screening and evidence that the MRSA lung
infection has persisted for at least 6 months prior to screening;
7. have FEV1 % predicted ≥30% and ≤100% normalized for age, gender, and height at screening;
8. evidence, defined as 1 or both of the following, that the persistent MRSA lung infection is suspect-
ed to be causing health consequences; have had at least 1 episode of acute pulmonary infection
treated with non-maintenance antibiotics within 12 months from screening (initiation of treat-
ment with intermittent inhaled anti-Pseudomonas therapy will not qualify as treatment with non-
maintenance antibiotics); requires anti-MRSA treatment as part of a maintenance regimen to pre-
vent pulmonary exacerbations or other respiratory symptoms;
9. be able to perform all the techniques necessary to use the AeroVanc inhaler and measure lung
function;
10.be able to produce expectorated sputum samples or be able and willing to undergo standardized
sputum induction;
11.agree not to smoke from screening through the end of the study;
12.females of child-bearing potential are eligible to participate in this study only if they are NOT preg-
nant or lactating, and if they are using a highly effective method of birth control;
13.participants with P. aeruginosa co-infection must either be stable on a regular suppression regi-
men of inhaled antibiotics or must be, in the opinion of the investigator, stable despite the lack of
NCT01746095 
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such treatment. Participants on a Cayston-based therapy must have received at least 2 cycles of
Cayston prior to baseline (can be 2 consecutive months or 2 cycles over 4 months).
Interventions Treatment group: A 28-day course of inhaled vancomycin (AeroVanc) starting at 32 mg twice per
day, and either (a) increased (64 mg twice per day), (b) kept the same (32 mg twice per day), or (c)
reduced (16 mg twice per day) pending initial safety evaluation.
Control group: A 28-day course of placebo inhalation powder.
Outcomes Primary outcome measure
1. Change from baseline at Day 29 of the dosing period (start of AeroVanc/Placebo administration is
considered Day 1 of the dosing period) in the number of MRSA CFUs in sputum culture.
Secondary outcome measures
1. Change from baseline in each pulmonary function test.
2. Change from baseline in Cystic Fibrosis Respiratory Symptom Diary scores.
3. Change from baseline in MRSA sputum density.
4. Time from start of dosing to first administration of other antimicrobial medications (oral, intra-
venous and/or inhaled) due to respiratory symptoms.
5. Time from start of dosing to exacerbation of signs/symptoms (Fuchs criteria).
6. Change from baseline in high sensitivity C-reactive protein and blood neutrophils.
Starting date March 2013.
Contact information Elliott Dasenbrook, MD. Case Western Reserve University School of Medicine and Rainbow Babies
and Children's Hospital.
Notes Study completed November 2014. No results posted as of 14th December 2014.
NCT01746095  (Continued)
CF: cystic fibrosis
CFTR: cystic fibrosis transmembrane conductance regulator
CFU: colony forming unit
DMC: Data Monitoring Committee
FEV1: forced expiratory volume at one second
MRSA: meticillin-resistant Staphylococcus aureus
P. aeruginosa : Pseudomonas aeruginosa




A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE (1950 - December 2014) and Embase (1980 - December 2014)
 
1 Embase, MEDLINE (methicillin AND resistant AND staphylococcus AND aureus OR
MRSA OR methicillin AND resistant AND staphylococcus AND aureus
OR methicillin AND staphylococcus).ti,ab
40457 Apply Limits
2 Embase, MEDLINE (cystic AND fibrosis).ti,ab 68893 Apply Limits
 
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis (Review)









Cochrane Database of Systematic Reviews
3 Embase, MEDLINE (eradication OR eradica*).ti,ab 86661 Apply Limits
4 Embase, MEDLINE 1 AND 2 AND 3 38 Apply Limits
  (Continued)
 
W H A T ' S   N E W
 
Date Event Description
18 February 2015 New citation required but conclusions
have not changed
Given that no new data have been added to this review, our con-
clusions remain the same.
18 February 2015 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders Group's Cys-
tic Fibrosis Trials Register identified no new studies to be includ-
ed in this review.
A search of PUBMED, Embase and MEDLINE identified a further
three studies, none of which were eligible for inclusion in the
analysis (Dalbøge 2013; Serisier 2004; Vanderhelst 2013).
A search of the ongoing trials registers (www.clinicaltrials.gov;
www.isrctn.org) identified one further ongoing study, which has
been listed in the review (NCT01746095).
 
C O N T R I B U T I O N S   O F   A U T H O R S
 
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draI the protocol David Lo
Review stage: select which trials to include (2 + 1 arbiter) David Lo, Matthew Hurley, Marianne Muhlebach, Alan
Smyth
Review stage: extract data from trials (2 people) David Lo, Matthew Hurley
Review stage: enter data into RevMan David Lo
Review stage: carry out the analysis David Lo, Matthew Hurley
Review stage: interpret the analysis David Lo, Matthew Hurley, Marianne Muhlebach, Alan
Smyth
Review stage: draI the final review David Lo, Matthew Hurley
Update stage: update the review David Lo
 
D E C L A R A T I O N S   O F   I N T E R E S T
David Lo and Matthew Hurley: none known.
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Marianne Muhlebach is one of the principle investigators for a randomised controlled study evaluating early treatment of MRSA; this study
is currently in progress (NCT01349192).
Alan Smyth is the Co-ordinating Editor of the Cochrane Cystic Fibrosis and Genetic Disorders Group and declares relevant activities
of: membership of a REMPEX steering committee; consultancies for Novartis, Biocontrol and Rempex Pharma (both make aerosolised
antibiotics which are active against some strains of Staphylococcus aureus); and also a lecture paid for by Chiesi Pharma.
S O U R C E S   O F   S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane
Cystic Fibrosis and Genetic Disorders Group.
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
In the 2015 update we have changed the spelling of 'methicillin' to 'meticillin' in line with the change in the international non-proprietary
name (although we are aware that in some parts of the world the drug is still known as methicillin).
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Methicillin-Resistant Staphylococcus aureus;  Anti-Bacterial Agents  [*therapeutic use];  Cystic Fibrosis  [*microbiology];  Drug Therapy,
Combination;  Randomized Controlled Trials as Topic;  Rifampin  [*therapeutic use];  Staphylococcal Infections  [*drug therapy]; 
Trimethoprim, Sulfamethoxazole Drug Combination  [*therapeutic use]
MeSH check words
Humans
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